Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Subcutaneous daratumumab shows benefit in patients with relapsed or refractory multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 544
Rating:

Dr Ajai Chari - Mount Sinai Hospital, New York, USA

Dr Chari speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated results from the phase Ib PAVO study.

He outlines how subcutaneous drug administration is possible with a mix of daratumumab and hyaluronidase, which curtails infusion time from hours to minutes and increases efficacy compared to IV administration. 

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation